TECHNOLOGY
“ We ' ve been able to identify a lot of genetic factors that contribute to differences in responses ”
DANIEL STREETMAN MANAGER IN CLINICAL EFFECTIVENESS , WOLTERS KLUWER HEALTH patients from Black populations . I think we ' re starting to see some of the benefits of this pay off .”
In the next decade , Wolters Kluwer will focus on continuing to build its pharmacogenomics database . “ We ' ve known about inheritable factors that contribute to differences in drug response for more than 50 years . For much of those early years , it was focused on what one gene describes . Now we have a much better understanding ”, says Streetman . “ I think we ' re in a much better position now , as far as understanding all the different factors that can contribute to these differences in how people respond , than we were five years ago or 10 years ago .”
healthcareglobal . com 79